Not all research peptides are equal in terms of published evidence, research interest, or the quality of available data. This guide covers the five compounds that UK researchers are most actively studying in 2026, based on citation metrics, active clinical trial programmes, and institutional research volume. Each entry includes the core research rationale and a summary of the evidence base.
All compounds discussed are Research Use Only and available from stock with >99% analytical purity.
1. Retatrutide — The Phase III Metabolic Frontier
Why researchers are studying it: Retatrutide (LY3437943) is the only triple-agonist peptide currently in Phase III clinical trials. Its simultaneous activation of GLP-1, GIP, and glucagon receptors represents a mechanistically novel approach that dual-agonist compounds cannot replicate. The glucagon component — absent in semaglutide and tirzepatide — adds hepatic energy expenditure via lipid oxidation and thermogenesis as a third axis.
The landmark evidence: Jastreboff et al., New England Journal of Medicine, 2023 (Phase II, n=338) reported a mean body weight reduction of -24.2% at 48 weeks — the strongest efficacy signal ever documented for a metabolic peptide in a published clinical trial. The Phase III TRIUMPH programme (NCT05929066, NCT05929079) is currently recruiting at 45+ centres.
Who is studying it: Academic groups focused on adiposity biology, hepatic metabolism, and incretin pharmacology. Pre-clinical researchers modelling NASH, type 2 diabetes, and cardiovascular risk factors.
Research context: At the molecular level, retatrutide binds the GLP-1 receptor with an EC50 of approximately 0.1 nM. The C18 fatty acid modification extends plasma half-life to ~6 days, enabling weekly dosing in clinical models. Pre-clinical data from Coskun et al. (Cell Metabolism, 2022) demonstrate up to 80% reduction in hepatic fat content in murine models.
2. BPC-157 — The Most Published Repair Peptide
Why researchers are studying it: BPC-157 (Body Protection Compound 157) has the deepest research literature of any synthetic repair peptide currently available. With over 100 peer-reviewed publications — predominantly from the University of Zagreb group — it has been studied across a remarkable range of tissue repair contexts including tendon, ligament, muscle, intestinal, and corneal repair.
The evidence base: The mechanistic data converges on several pathways: upregulation of VEGFR2 for angiogenesis, NO (nitric oxide) pathway modulation for vasodilation, and growth hormone receptor sensitisation in fibroblasts. Sikiric et al. have published extensively on its gastroprotective and systemic healing properties across three decades.
Who is studying it: Sports science researchers (muscle and tendon repair models), gastroenterology researchers (intestinal fistula and inflammatory bowel disease models), and neuroscience groups (dopaminergic and serotonergic pathway modulation).
Research context: BPC-157 is a 15-amino-acid synthetic pentadecapeptide derived from a gastric mucosal protein. It is notably stable in acidic conditions — relevant to gastrointestinal research models. The NO-dependent pathway is considered central to its angiogenic properties.
3. GHK-Cu — The Gene Expression Modulator
Why researchers are studying it: GHK-Cu (Glycine-Histidine-Lysine Copper Complex) is unique among research peptides in the breadth of its documented genomic effects. A genome-wide microarray study by Pickart et al. (2012) demonstrated that GHK-Cu modulates the expression of over 4,000 human genes — approximately 31% of those studied — including significant upregulation of collagen synthesis enzymes, elastin, and antioxidant defence genes.
The evidence base: Published primarily in International Journal of Molecular Sciences and Biomedicines, the GHK-Cu literature spans wound healing, hair follicle biology, anti-inflammatory signalling, and neurotrophin expression. Collagen synthesis has been shown to increase by up to 70% in fibroblast cultures.
Who is studying it: Dermatology research groups (wound healing and skin regeneration), hair biology researchers (follicle cycling and dermal papilla stimulation), and anti-ageing researchers (gene expression modulation).
Research context: GHK-Cu was first isolated from human plasma albumin in 1973 by Pickart. Its blue colour in solution (from the Cu²⁺ complex) and distinct dark blue-grey lyophilised appearance distinguishes it from other peptides visually.
4. MOTS-c — Mitochondrial Signalling Research
Why researchers are studying it: MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is scientifically exceptional for one reason: it is the first hormone discovered to be encoded by mitochondrial DNA. Identified by Lee et al. at USC in 2015, it represents a paradigm shift in our understanding of mitochondria as signalling organs, not merely energy factories.
The evidence base: Lee et al., Cell Metabolism, 2015 established that MOTS-c activates the AMPK (AMP-activated protein kinase) pathway — the master regulator of cellular energy homeostasis — and demonstrated improved insulin sensitivity and reduced adipogenesis in diet-induced obesity mouse models. Circulating MOTS-c levels decline with age in both rodents and humans, making it a subject of longevity research interest.
Who is studying it: Metabolic biology groups (insulin signalling, AMPK pathway), longevity researchers, exercise physiology groups (skeletal muscle glucose uptake), and mitochondrial medicine researchers.
Research context: MOTS-c is a 16-amino-acid peptide with a sequence encoded within the 12S ribosomal RNA gene of the human mitochondrial genome — an unprecedented finding that prompted significant re-evaluation of mitochondrial biology.
5. TB-500 — The Actin Dynamics Compound
Why researchers are studying it: TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in virtually all nucleated cells. The specific active fragment (amino acids 17–23) retains the core actin-sequestering activity of the full molecule with improved stability. Its fundamental role in actin polymerisation and cell migration makes it relevant to any research context involving tissue repair, wound closure, or cellular regeneration.
The evidence base: Bock-Marquette et al., Nature, 2004 established the cardiac repair potential of Thymosin Beta-4 in a murine myocardial infarction model — one of the most cited papers in cardiac regeneration research. RegeneRx Biopharmaceuticals has advanced full-length Tβ4 into Phase II clinical trials for dry eye disease and dermal wound healing.
Who is studying it: Cardiac regeneration researchers, wound healing and dermatology groups, sports science researchers (skeletal muscle regeneration), and ophthalmology researchers.
Research context: The TB-500 fragment corresponds to the actin-binding domain of Thymosin Beta-4. Its capacity to upregulate actin dynamics is mechanistically linked to its downstream effects on cell migration, angiogenesis, and tissue remodelling.
Selecting the Right Compound
The “best” peptide is entirely context-dependent. The five compounds above represent the strongest evidence bases in their respective research areas. For researchers at the start of a programme:
- Metabolic research: Start with retatrutide’s published Phase II data (NEJM 2023) as a baseline
- Tissue repair: BPC-157 offers the largest published dataset
- Genomics/skin biology: GHK-Cu’s microarray data (4,000+ genes) offers unusually broad scope
- Mitochondrial biology: MOTS-c’s novelty as a mitokine offers unexplored research avenues
- Actin biology/cardiac: TB-500/Tβ4 has solid in vivo data and a clinical development track record
All five are available from UK Peptides at >99% analytical purity, EU warehouse, with tracked shipping to the UK.
All products are Research Use Only. Not for human consumption.